Silver Creek is a clinical-stage biotechnology company headquartered in San Francisco, CA. Our Smart Growth Factor™ technology enables the rapid development of growth factor fusion proteins that are designed to target and heal damaged tissues. Our lead asset, scp776, is a first-in-class, targeted fusion protein that harnesses the cell survival function of IGF-1. Scp776 is currently being evaluated in ARPEGGIO, a Phase II study for the treatment of acute ischemic stroke.